Novartis Strengthens Next-Generation ADC Platform with Myricx Bio Acquisition
Novartis has announced that it will acquire U.K.-based biotech company Myricx Bio.
The transaction is drawing attention as another signal that, in ADCs, differentiation is increasingly moving beyond tumor target selection and toward payload innovation.
Deal Highlights
- $1.1B upfront; total potential value of up to $1.5B
- Next-generation ADC platform using N-myristoyltransferase inhibitor (NMTi) payload technology
- Potential to address resistance and tolerability limitations in existing ADC approaches
- U.K. biotech built on academic-origin science
- Closing expected in the second half of 2026
Myricx Bio is developing NMTi payload technology for antibody-drug conjugates. In ADC development, the payload mechanism and therapeutic window are becoming as important to differentiation as tumor antigen selection.
The $1.1 billion upfront payment is notable for a platform that has not yet reached late-stage clinical development. It suggests that strategic value is being placed on payload technology itself, not only on individual drug candidates.
The deal also reflects the role of external innovation in oncology, as academic-origin science moves from biotech formation into large pharma pipeline strategy.
Congratulations to both teams at Novartis and Myricx Bio.